A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Vosaroxin (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Sunesis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 06 Jun 2012 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from active, no longer recruiting to completed.